Risitano, Antonio M.

Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria

Hillmen, P., Szer, J., Weitz, I., Röth, A., Höchsmann, B., Panse, J., Usuki, K., Griffin, M., Kiladjian, J.-J., de Castro, C., et al. (2021) · New England Journal of Medicine

Complement system in diseasesHemophilia Treatment and Research

Cited by 440

Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy

Mastellos, D. C., Pires da Silva, B. G. P., Fonseca, B. A. L., Fonseca, N. P., Auxiliadora-Martins, M., Mastaglio, S., Ruggeri, A., Sironi, M., Radermacher, P., Chrysanthopoulou, A., et al. (2020) · Clinical Immunology

Complement system in diseasesCOVID-19 Clinical Research Studies

Cited by 255

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: An open-label, single-arm, phase 2, proof-of-concept trial

Risitano, A. M., Röth, A., Soret, J., Frieri, C., de Fontbrune, F. S., Marano, L., Alashkar, F., Benajiba, L., Marotta, S., Rozenberg, I., et al. (2021) · The Lancet Haematology

Complement system in diseasesHemophilia Treatment and Research

Cited by 110

Immune insights into AA

Risitano, A. M. (2017) · Blood

Blood disorders and treatmentsHematopoietic Stem Cell Transplantation

Cited by 3